Is VectorBuilder profitable in 2026?

VectorBuilder states it was profitable even before raising outside capital, according to its own July 26, 2023 unicorn announcement. No audited public financials exist since the company is private, and no contradicting statement about losses has been issued through mid-2026.

Who owns VectorBuilder and is it public?

VectorBuilder is privately held, founded in 2014 by University of Chicago geneticist Dr. Bruce Lahn. It reached a $1B+ unicorn valuation on July 26, 2023 after a $57 million Series C in November 2022, with Legend Capital named as an investor.

Could AI replace VectorBuilder's gene vector business?

AI could commoditize VectorBuilder's free bioinformatics design tools, but its core revenue comes from wet-lab cloning, GMP manufacturing, patented backbones like MiniVec and MuteFree, and regulatory work, which require physical infrastructure AI cannot replicate as of 2026.

Who is VectorBuilder's biggest competitor?

In VectorBuilder's targeted clinical CDMO growth segment, Merck launched a competing VirusExpress 293 AAV platform in August 2025, while Thermo Fisher acquired Mirus Bio and Lonza and WuXi AppTec also operate in the same gene therapy manufacturing space.

Has VectorBuilder raised new funding since becoming a unicorn?

No new funding round has been publicly disclosed since VectorBuilder's $57 million Series C closed in November 2022, which pushed it to a $1B+ valuation on July 26, 2023. As of July 2026 that is roughly a three-year gap without an announced raise.

What is VectorBuilder's Ikarovec partnership worth?

On January 6, 2026, VectorBuilder signed an exclusive worldwide option agreement licensing its intravitreal AAV capsid technology to UK biotech Ikarovec for its IKAR-003 eye gene therapy, a deal potentially worth over $1 billion if the option converts to a full partnership.

United States · United States

VectorBuilder

Custom gene vector maker and GMP CDMO for research and clinical gene therapy work.

Protection under test

Assessed 29 July 2026 · Evidence as of 29 July 2026

Something worth protecting exists and is being tested right now.

On the recordSince 29 July 2026 · Checkable from mid-2026 · Every call on the record Checkpoint: Ikarovec option conversion decision from the January 2026 deal

The call

The research vector business looks hard to dislodge, while the CDMO bet that justifies the unicorn price sits in a lane Merck and Thermo Fisher just entered.

VectorBuilder runs two separate businesses: it makes custom viral vectors (the genetic packages scientists use to deliver genes into cells) for research labs worldwide, and it also produces clinical-grade versions for drug companies making gene therapies. The research business is hard for giants like Merck and Thermo Fisher to compete in because they only want huge, standardized orders, while VectorBuilder handles thousands of small custom orders that add up to real money. The clinical side is the real challenge, though, because now Merck, Thermo Fisher, Lonza, WuXi, and Charles River are all offering similar products with more money and established relationships. The company's value depends almost entirely on whether its clinical business can grow fast enough to justify its high price tag before these competitors take over, and the next 6 months will show whether its key partnerships and product deals actually gain traction or stall out.

Why

AI pressure: AI-assisted sequence design and codon optimization tools. Free AI tools are squeezing the front-end design step, but wet-lab synthesis and GMP production stay untouched. Could AI do the core job? Unlikely.

Bigger players: Merck (VirusExpress 293 AAV platform), Thermo Fisher (Mirus Bio), Lonza, WuXi AppTec. Merck and Thermo now sell competing AAV and CDMO platforms aimed at the same clinical manufacturing customers VectorBuilder wants to keep. Could a giant copy it? Probably.

What protects it. 80,000 custom orders a year across 4,500 institutions in 90+ countries, a long-tail catalog too fragmented for giants to chase profitably.

What would change this call

Merck or Thermo Fisher announce named CDMO contract wins previously held or pursued by VectorBuilder. Would show incumbents actively displacing VectorBuilder in clinical manufacturing.
VectorBuilder's Ikarovec option converts into a full partnership or lapses within 2026. Would confirm or undercut the CDMO growth thesis behind its valuation.
VectorBuilder raises a new funding round at a flat or reduced valuation versus 2023's $1B mark. Would indicate investor doubt about CDMO expansion despite research-side strength.

Key numbers

80,000+ custom vectors built per year (2023-12-08)
4,500+ institutions served worldwide (2024-11-18)
$57M Series C closed, hit $1B valuation (2022-11)

Named risks

Clinical CDMO segment faces better-capitalized incumbents (Merck, Thermo Fisher) shipping competing platforms since 2025. Severity: high
No new funding round disclosed since July 2023, a roughly three-year gap despite expanding partnerships. Severity: medium
Unresolved headcount discrepancy between company's 2023 claim of 600 plus employees and much smaller third-party tracker figures. Severity: medium
Ikarovec deal is only an option agreement as of January 2026 and may not convert into a full strategic partnership. Severity: medium
No audited public financials exist to confirm actual revenue scale of the private company. Severity: low

Rivals, as read in July 2026

Rival	Direction	Evidence
Merck	gaining on	Launched competing VirusExpress 293 AAV platform in August 2025, targeting VectorBuilder's CDMO segment
Thermo Fisher Scientific	gaining on	Acquired Mirus Bio to strengthen gene delivery manufacturing capabilities, reported by Dec 2025
Lonza	contesting	Established large-scale viral vector CDMO incumbent competing in same clinical manufacturing space
WuXi AppTec	contesting	Competing CDMO with greater capitalization active in gene and cell therapy manufacturing
Addgene	contesting	Nonprofit plasmid repository competing in academic long-tail research vector distribution

Questions people ask

Is VectorBuilder profitable in 2026?: VectorBuilder states it was profitable even before raising outside capital, according to its own July 26, 2023 unicorn announcement. No audited public financials exist since the company is private, and no contradicting statement about losses has been issued through mid-2026.
Who owns VectorBuilder and is it public?: VectorBuilder is privately held, founded in 2014 by University of Chicago geneticist Dr. Bruce Lahn. It reached a $1B+ unicorn valuation on July 26, 2023 after a $57 million Series C in November 2022, with Legend Capital named as an investor.
Could AI replace VectorBuilder's gene vector business?: AI could commoditize VectorBuilder's free bioinformatics design tools, but its core revenue comes from wet-lab cloning, GMP manufacturing, patented backbones like MiniVec and MuteFree, and regulatory work, which require physical infrastructure AI cannot replicate as of 2026.
Who is VectorBuilder's biggest competitor?: In VectorBuilder's targeted clinical CDMO growth segment, Merck launched a competing VirusExpress 293 AAV platform in August 2025, while Thermo Fisher acquired Mirus Bio and Lonza and WuXi AppTec also operate in the same gene therapy manufacturing space.
Has VectorBuilder raised new funding since becoming a unicorn?: No new funding round has been publicly disclosed since VectorBuilder's $57 million Series C closed in November 2022, which pushed it to a $1B+ valuation on July 26, 2023. As of July 2026 that is roughly a three-year gap without an announced raise.
What is VectorBuilder's Ikarovec partnership worth?: On January 6, 2026, VectorBuilder signed an exclusive worldwide option agreement licensing its intravitreal AAV capsid technology to UK biotech Ikarovec for its IKAR-003 eye gene therapy, a deal potentially worth over $1 billion if the option converts to a full partnership.

Timeline

2026-06-23Announced strategic partnership with MaxCyte combining MiniVec with Flow Electroporation for CAR-T manufacturing
2026-05-05Granted European patent for MiniVec plasmid backbone
2026-04Launched MuteFree AAV backbone to address ITR instability
2026-01-06Signed exclusive worldwide option deal with Ikarovec potentially worth over $1 billion
2025-08Merck launched competing VirusExpress 293 AAV platform
2024-11-18Won BioIndustrial Innovation of the Year Award, cited 4,500+ institutional customers
2023-07-26Reached unicorn status with $1B+ valuation after fresh cash injection
2022-11Closed $57 million Series C funding round
2014Founded by Dr. Bruce Lahn in Chicago

Revision history

29 July 2026

First assessed. Protection under test. The text above is fixed as of this date and is not edited afterwards.

In the same band

Ford Motor Whirlpool Solventum